Golimumab (Simponi®, Simponi Aria®): A Comprehensive Pharmacological and Clinical Review

I. Introduction and Overview

1.1. Executive Summary

Golimumab is a fully human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that functions as a high-affinity antagonist of tumor necrosis factor-alpha (TNF-α), a pivotal cytokine in the pathophysiology of numerous inflammatory conditions.[1] Developed and marketed by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, golimumab represents a significant therapeutic advancement in the management of chronic, immune-mediated inflammatory diseases.[3] It is available under two distinct brand names corresponding to its route of administration: Simponi® for subcutaneous (SC) injection and Simponi Aria® for intravenous (IV) infusion.[3] The fundamental therapeutic principle of golimumab is the neutralization of excess TNF-α, which in turn interrupts the downstream inflammatory cascade responsible for tissue damage and clinical symptoms. This mechanism has demonstrated efficacy in reducing disease activity, improving physical function, and, in several key indications, inhibiting the progression of structural joint damage.[5]

1.2. Drug Identification

• [Generic Name:] Golimumab [2]
• [DrugBank ID:] DB06674 [2]
• [CAS Number:] 476181-74-5 [1]
• [Type:] Biotech, Monoclonal Antibody (mAb), Protein-Based Therapy [2]
• [Other Names:] CNTO-148 [3]
• [Chemical Formula & Weight:] The protein has a chemical formula of C6530​H10068​N1752​O2026​S44​ and an average molecular weight of 146,943.1937 Daltons.[2]

1.3. Place in Therapy